5 Conclusions The absence of any effects of hepatic impairment on the PK of tirzepatide would suggest that a dose adjustment of tirzepatide, based on PK parameters, may not be required in people with hepatic impairment
Molecular pathways documented in preclinical research include: (1) activation of nitric oxide (NO) synthesis via L-arginine/eNOS pathway, (2) transcriptional upregulation of VEGF-A and FGF-2 favouring angiogenesis, (3) modulation of the Egr-1 early transcription factor involved in fibroblast proliferation, (4) interaction with 5-HT2A and dopaminergic receptors in some behavioural models, (5) stabilisation of endothelial function via eNOS modulation and reduction of oxidative stress (8-OH-dG, MDA)
The launch comes amid growing consumer awareness of the relationship between oxidative stress, lifestyle demands, and long-term wellness
Researchers are now starting to investigate whether similar benefits could be seen with semaglutide
10.5603/FM.a2020.0075 154 ZhangB.ZhengF.LiuA.LiZ.ZhengF.LiuQ.et al (2021)